BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Research analysts at HC Wainwright dropped their Q3 2025 earnings per share estimates for BioCryst Pharmaceuticals in a research report issued on Tuesday, August 5th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of $0.02 per share for the quarter, down from their previous estimate of $0.13. HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals' Q4 2025 earnings at $0.03 EPS, FY2025 earnings at $0.07 EPS, FY2026 earnings at $0.31 EPS, FY2027 earnings at $0.71 EPS, FY2028 earnings at $1.24 EPS and FY2029 earnings at $1.87 EPS.
A number of other equities analysts have also commented on BCRX. Wedbush lifted their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a research note on Monday, June 30th. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price objective on the stock. Bank of America lifted their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Tuesday, July 1st. Wall Street Zen raised BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 26th. Finally, JPMorgan Chase & Co. lifted their price objective on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $16.70.
Check Out Our Latest Stock Report on BioCryst Pharmaceuticals
BioCryst Pharmaceuticals Stock Performance
Shares of NASDAQ:BCRX traded down $0.05 during midday trading on Thursday, hitting $8.30. 1,823,000 shares of the stock were exchanged, compared to its average volume of 3,745,884. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -46.11, a P/E/G ratio of 1.90 and a beta of 1.10. The business's 50-day moving average price is $9.32 and its 200 day moving average price is $8.75. BioCryst Pharmaceuticals has a 12 month low of $6.01 and a 12 month high of $11.31.
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. The business's revenue for the quarter was up 49.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.06) earnings per share.
Hedge Funds Weigh In On BioCryst Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. acquired a new position in BioCryst Pharmaceuticals in the second quarter valued at approximately $229,000. Creative Planning lifted its stake in BioCryst Pharmaceuticals by 11.3% in the second quarter. Creative Planning now owns 86,197 shares of the biotechnology company's stock valued at $772,000 after buying an additional 8,748 shares during the period. SG Americas Securities LLC lifted its stake in BioCryst Pharmaceuticals by 441.5% in the second quarter. SG Americas Securities LLC now owns 235,532 shares of the biotechnology company's stock valued at $2,110,000 after buying an additional 192,036 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its stake in BioCryst Pharmaceuticals by 8.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 49,202 shares of the biotechnology company's stock valued at $441,000 after buying an additional 3,998 shares during the period. Finally, Geode Capital Management LLC lifted its stake in BioCryst Pharmaceuticals by 1.9% in the second quarter. Geode Capital Management LLC now owns 5,054,610 shares of the biotechnology company's stock valued at $45,296,000 after buying an additional 93,973 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.
About BioCryst Pharmaceuticals
(
Get Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Further Reading
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
